The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
NCT01707849
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Hepatitis C Recurrence After Liver Transplant
Interventions
DRUG:
EVL arm
DRUG:
MMF arm
Sponsor
Hospital Vall d'Hebron